ストックスクリーナーアプリを入手
4.55
3.41%
0.15
前日終値:
$4.40
開ける：
$4.41
24時間の取引高:
2.10M
Relative Volume:
0.87
時価総額：
$356.57M
収益：
$409.00K
当期純損益:
$-101.35M
株価収益率:
-2.7744
EPS:
-1.64
ネットキャッシュフロー:
$-71.49M
1週間 パフォーマンス:
+9.37%
1か月 パフォーマンス:
-23.79%
6か月 パフォーマンス:
-32.99%
1年 パフォーマンス:
-35.37%
1日の値動き範囲:
$4.37
$4.62
1週間の範囲:
$4.12
$4.75
52週間の値動き範囲:
$3.553
$11.16
Altimmune Inc Stock (ALT) Company Profile
ALT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
4.55 | 356.57M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-28 | 開始されました | William Blair | Mkt Perform |
| 2025-01-08 | 開始されました | Stifel | Buy |
| 2024-11-12 | 開始されました | UBS | Buy |
| 2024-04-29 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-01-24 | 開始されました | Goldman | Neutral |
| 2023-03-22 | ダウングレード | Goldman | Buy → Neutral |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-11 | 開始されました | Guggenheim | Buy |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-11-12 | 繰り返されました | B. Riley Securities | Buy |
| 2020-09-25 | 開始されました | B. Riley FBR | Buy |
| 2020-08-14 | 開始されました | Evercore ISI | Outperform |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-07-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-02-24 | 再開されました | ROTH Capital | Buy |
| 2019-07-19 | 開始されました | ROTH Capital | Buy |
| 2017-10-09 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Altimmune Inc (ALT) 最新ニュース
Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com
Altimmune's US$42m Market Cap Fall Books Insider Losses - Yahoo Finance
Coulter Partners places seasoned biopharmaceutical industry executives to Altimmune Board of Directors - Hunt Scanlon Media
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com Canada
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
H.C. Wainwright maintains Buy rating on Altimmune stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Altimmune stock - Investing.com India
8 Analysts Assess Altimmune: What You Need To Know - Benzinga
Altimmune’s Pemvidutide: A Promising Catalyst with Blockbuster Potential and Strong Financial Backing - TipRanks
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN
PharmAthene stock hits 52-week low at $5.1 amid challenges By Investing.com - Investing.com South Africa
PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo
Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha
Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada
Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa
Altimmune rises as buyout rumors follow R&D updates - MSN
Altimmune CFO Gregory Weaver purchases $51,996 in stock By Investing.com - Investing.com Australia
Altimmune Outlines Pemvidutide Plans In MASH And Beyond - insights.citeline.com
Altimmune soars amid takeover speculation - MSN
Altimmune stock rises amid buyout and R&D news(ALT:NASDAQ) - Seeking Alpha
(ALT) Trading Advice - Stock Traders Daily
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Benzinga
Stifel maintains Buy on Altimmune stock, $18 price target - Investing.com India
Stifel maintains Buy on Altimmune stock, $18 price target By Investing.com - Investing.com UK
Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions - TradingView
Altimmune CFO Gregory Weaver purchases $51,996 in stock - Investing.com India
Citizens JMP reiterates Altimmune stock with $25 target By Investing.com - Investing.com South Africa
Citizens JMP reiterates Altimmune stock with $25 target - Investing.com
Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook - TipRanks
Altimmune to test obesity drug for alcohol use disorder and related health conditions - TradingView
Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions - TradingView
Altimmune Inc (ALT) 財務データ
収益
当期純利益
現金流量
EPS
Altimmune Inc (ALT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
2.51%
大文字化:
|
ボリューム (24 時間):